Top Analyst Reports for NVIDIA, Walmart & AbbVie

Wednesday, November 11, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> AI Trade Comes Back Post-CoreWeave Numbers

Today's Featured Research Reports

NVIDIA’s shares have underperformed the Zacks Semiconductor - General industry over the past year (-12.9% vs. -3.7%). Per the Zacks analyst, China's restrictions limit data center opportunities for the company, while customer concentration, rising investment needs, supply commitments and credit guarantees increase business risks. Intensifying competition adds uncertainty.

However, broad AI infrastructure demand, Blackwell Ultra adoption and the expanding Vera Rubin platform strengthen NVIDIA's growth prospects. Customer diversification, product leadership and expanding software opportunities support its outlook.

(You can read the full research report on NVIDIA here >>>)

Walmart’s shares have outperformed the Retail - Supermarkets industry over the past year (+21.4% vs. +20.4%). The Zacks analyst believes that the company benefits from its scale, value positioning and strong omnichannel model. Healthy traffic, e-commerce growth, expanding advertising and membership businesses, and international diversification support its growth prospects.

Yet, elevated operating costs, pharmacy-related sales pressure and heavy capital spending weigh on profitability. Price investments may constrain margins, while currency fluctuations add uncertainty.

(You can read the full research report on Walmart here >>>)

AbbVie’s shares have outperformed the Medical - Products  industry over the last six months (+41.4% vs. +28.4%). The Zacks analyst believes the company has offset Humira's patent-related sales decline with strong growth from Skyrizi and Rinvoq. Its expanding neuroscience portfolio, robust pipeline, new indication approvals and strategic acquisitions support long-term growth prospects.

However, Humira's continuing erosion, slowing oncology sales and macroeconomic pressures on its Aesthetics business remain significant challenges.

(You can read the full research report on AbbVie here >>>)

Pioneer’s shares have outperformed the Zacks Banks - Northeast  industry over the past year (+37.7% vs. +27.2%). The Zacks analyst believes that the company benefits from wider spreads, deposit and loan growth, specialty-finance expansion and diversified fee-based businesses. Generally stable asset quality and a solid capital position support growth initiatives.

Yet acquisition-related expenses, litigation risks, higher funding costs and rising charge-offs could pressure profitability. Capital-ratio compression may also limit financial flexibility.

(You can read the full research report on Pioneer here >>>)

Aspira’s shares have underperformed the Zacks Medical - Instruments  industry over the past year (-66.6% vs. +24.5%). The Zacks analyst believes that the company faces liquidity constraints, financing dependence and weakness in its core business. Its investment case remains highly execution-dependent, with significant risks surrounding commercialization and pipeline development.

However, ENDOinform targets an underserved market, while clinical validation and the Cleveland Clinic partnership offer growth potential. An established distribution network could also support future product launches.

(You can read the full research report on Aspira here >>>)

Other noteworthy reports we are featuring today include Morgan Stanley (MS), CVS Health Corp. (CVS) and General Dynamics Corp. (GD).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

AbbVie's (ABBV) Skyrizi, Rinvoq Key to Top-Line Growth

Walmart (WMT) Gains From Advertising & Membership Businesses

NVIDIA's (NVDA) Data Center Biz Gains From Growing Adoption of GPUs

Featured Reports

Increasing Orders Drive General Dynamics (GD) Amid Labor Shortage
Per the Zacks analyst, General Dynamics is likely to benefit from increasing orders from the Pentagon and US allies. Yet labor shortage result in delays and likely impact operating results.

CVS Health (CVS) Banks on Health Services Strength, Macro Woes Stay
The Zacks analyst is impressed with CVS Health consistently benefiting from pharmacy drug mix and brand inflation, aiding its Health Services top line. Macroeconomic pressures can escalate its costs.

Wabtec (WAB) Gains From Installed Base Aftermarket Amid Tariff Issues
Per the Zacks Analyst, Wabtec gains from a large installed base and long-cycle freight and transit spending, supporting aftermarket demand. Tariff and manufacturing cost pressure act as headwinds.

Solaris Energy (SEI) Poised for Growth on Strong Power Demand
The Zacks analyst believes that Solaris Energy is poised for sustained growth, driven by rising demand for behind-the-meter power and long-term contracts that enhance earnings visibility.

Strategic Acquisitions, IB Support Morgan Stanley (MS), High Costs Ail
Per the Zacks analyst, solid IB business, strategic alliances/acquisitions to diversify revenue mix and global footprint will support Morgan Stanley amid higher expenses and volatile trading business.

AGCO Corp (AGCO) Gains From Precision Ag Amid Weak Farm Demand
Per the Zacks analyst, AGCO benefits from precision ag adoption, and cost savings, while weak farm economics and sluggish equipment demand weigh on its growth prospects.

Rising Data Usage, Expansion Aid SBA Communications (SBAC), Churn Ails
Per the Zacks analyst, SBA Communications gains from rising data usage, carrier network expansion and international growth. However, carrier churn, concentration and interest expenses constrain growth

New Upgrades

Humana (HUM) Rides on Solid Medicare Business, Balance Sheet
Per the Zacks analyst, Humana's Medicare Advantage business remains a driving factor for its top line. Also, its strong balance sheet enables business investments that drive long-term growth.

Super Micro (SMCI) Gains From Traction in its Modular AI Server
Per the Zacks Analyst, strong demand for SMCI's modular AI infrastructure that integrates AMD and NVIDIA's latest chips strengthens its long-term performance.

Plexus Gains from New Program Ramps & Industrial Tailwinds
Per the Zacks analyst, Plexus is benefiting from new program ramps, funnel growth and industrial tailwinds. Strength in the aerospace and defense market sector is another plus.

New Downgrades

Ingredion (INGR) Faces Margin Pressure From Rising Costs and FX Risks
Per the Zacks analyst, Ingredion faces margin pressure from rising input and energy costs, tapioca inflation and currency headwinds, while delayed pricing recovery adds to profitability risks.

Cost Inflation & Investment Expenses Hurt Construction Partners (ROAD)
Per the Zacks analyst, increasing business expenses, mainly on acquisitions, are straining Construction Partners' prospects. Energy cost inflation and execution risks restrict profitability.

High Mortgage Rates & Development Costs Hurt D.R. Horton (DHI)
Per the Zacks analyst, D.R. Horton is hurting due to growing affordability concerns because of elevated mortgage rates. Also, high costs and incentive offerings are eroding margins.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research